At the 52nd annual meeting of the American Society of Hematology, which wraps up Tuesday, Novartis, Celgene and Seattle Genetics revealed the latest news from their studies on blood diseases and cancers. But despite some positi…
At the 52nd annual meeting of the American Society of Hematology, which wraps up Tuesday, Novartis, Celgene and Seattle Genetics revealed the latest news from their studies on blood diseases and cancers. But despite some positi…
Traditional chemotherapy for cancer patients is as dreaded as the disease itself. But Delcath’s “Chemosaturation System,” which is doing well so far in tests, promises to deliver treatments far more precisely, thus limiting sid…